CRDF
Cardiff Oncology, Inc.
There isn't enough reported data to score CRDF yet.
CRDF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CRDF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
CRDF PE Valuation
CRDF has no meaningful PE right now: it lost money over the past year.
CRDF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CRDF's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
CRDF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.55 | +$0.25 |
| Q2 2026 | -$0.60 | +$0.28 |
| Q1 2026 | -$0.67 | +$0.26 |
| Q4 2025 | -$0.69 | +$0.26 |
| Q3 2025 | -$0.80 | +$0.14 |
| Q2 2025 | -$0.88 | +$0.03 |
| Q1 2025 | -$0.93 | -$0.03 |
| Q4 2024 | -$0.95 | -$0.02 |
CRDF is still losing money, but far less than before: $0.55 per share over the past year, against $2.80 at its worst in late 2019.
CRDF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $171K | +43% |
| Q2 2026 | $104K | -14% |
| Q1 2026 | $41K | -62% |
| Q4 2025 | $243K | +61% |
| Q3 2025 | $120K | -27% |
| Q2 2025 | $121K | -26% |
| Q1 2025 | $109K | -47% |
| Q4 2024 | $151K | -3.2% |
CRDF's revenue is growing: $171,000 last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5391% | +4587 points |
| Q2 2026 | -9245% | +2967 points |
| Q1 2026 | -31341% | -18147 points |
| Q4 2025 | -3221% | +5105 points |
| Q3 2025 | -9978% | -2341 points |
| Q2 2025 | -12212% | -4516 points |
| Q1 2025 | -13195% | -7861 points |
| Q4 2024 | -8326% | -1703 points |
CRDF's operating margin was −5391% last quarter, up 4587 points from the same quarter a year ago.
CRDF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.9M | +$974K |
| Q4 2025 | -$6M | +$4.3M |
| Q3 2025 | -$10.9M | -$396K |
| Q4 2024 | -$10.3M | -$3.1M |
| Q3 2024 | -$10.5M | -$2.2M |
| Q2 2024 | -$9.2M | -$1.8M |
| Q1 2024 | -$7.8M | +$847K |
| Q4 2023 | -$7.1M | +$2.3M |
CRDF has burned cash in almost every quarter: −$39M over the past year, against −$38M the year before.
CRDF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +7.8M shares |
| 1 year | +14% | +9.3M shares |
| 3 years | +71% | +31.5M shares |
| 5 years | +97% | +37.4M shares |
| Available history | +669% | +66.3M shares |
CRDF has 76M diluted shares, up 14% from a year ago.
CRDF Net Leverage
CRDF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRDF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CRDF's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
CRDF PE vs Healthcare Sector
CRDF has no meaningful PE right now: it lost money over the past year.
CRDF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.96 | 24% below |
| 20 week MA | $1.01 | 28% below |
| 50 week MA | $1.57 | 54% below |
| 100 week MA | $2.35 | 69% below |
| 200 week MA | $2.29 | 68% below |
CRDF is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
CRDF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $18.9 | +1377% |
| 2021 | $18.9 | $6.45 | -66% |
| 2022 | $6.45 | $1.26 | -80% |
| 2023 | $1.26 | $1.48 | +17% |
| 2024 | $1.48 | $4.32 | +192% |
| 2025 | $4.32 | $3.17 | -27% |
| 2026 YTD | $3.17 | $0.73 | -77% |
CRDF's yearly returns have swung widely, from +1377% in 2020 to −80% in 2022. It's down 77% so far in 2026.